
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
E6BP Lentiviral Activation Particles (h) | sc-409673-LAC | 200 µl | $455.00 |
RCN2 encodes E6-binding protein (E6BP), a luminal endoplasmic reticulum protein implicated in calcium-dependent secretory pathway regulation and ER homeostasis. E6BP is thought to influence protein folding and trafficking through ER-associated quality control processes and may intersect with stress-response signaling that shapes cellular proteostasis. Altered regulation of ER-resident calcium-binding proteins, including E6BP, has been associated with changes in secretion, cell survival under stress, and phenotypes relevant to cancer biology and other disorders involving proteostasis imbalance. Human RCN2/E6BP therefore serves as a useful node for studying ER function, calcium handling, and secretion-linked signaling networks.
E6BP Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient RCN2 upregulation across a broader range of human cell types.
E6BP Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the RCN2 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous E6BP expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native RCN2 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.